These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2785000)

  • 1. Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
    Itoh K; Pellis NR; Balch CM
    Cancer Immunol Immunother; 1989; 29(1):57-62. PubMed ID: 2785000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.
    Toledano M; Mathiot C; Michon J; Andreu G; Lando D; Brandely M; Fridman WH
    Cancer Immunol Immunother; 1989; 30(1):57-64. PubMed ID: 2513112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor.
    Balch CM; Itoh K; Tilden AB
    Surgery; 1985 Aug; 98(2):151-7. PubMed ID: 3875156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
    Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
    Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of lymphokine activated killer cells in serum-free medium.
    Froelich CJ; Guiffaut S
    J Immunol Methods; 1986 Feb; 86(2):205-11. PubMed ID: 3484769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay.
    Kanamaru H; Yoshida O
    Urol Res; 1989; 17(4):259-64. PubMed ID: 2788951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of interleukin-2-activated lymphocytes for autologous normal blood mononuclear cells.
    Oshimi K; Oshimi Y; Saito H; Mizoguchi H
    J Immunol Methods; 1988 May; 109(2):161-8. PubMed ID: 3258896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
    Fox BA; Rosenberg SA
    Cancer Immunol Immunother; 1989; 29(3):155-66. PubMed ID: 2786456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human lymphokine-activated killer (LAK) cells: III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cells.
    Leung KH
    Cancer Immunol Immunother; 1991; 34(1):31-6. PubMed ID: 1760808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB; Itoh K; Balch CM
    J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induction by monocytes, depending on their functional state.
    Nii A; Sone S; Utsugi T; Yanagawa H; Ogura T
    Int J Cancer; 1988 Jan; 41(1):33-40. PubMed ID: 2826345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes.
    Han X; Itoh K; Balch CM; Pellis NR
    Lymphokine Res; 1988; 7(3):227-35. PubMed ID: 3263554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro.
    McVicar DW; Merchant RE; Merchant LH; Young HF
    Cancer Immunol Immunother; 1989; 29(3):211-8. PubMed ID: 2499421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.